Last reviewed · How we verify
NCT04525612
68Ga-BNU-PSMA PET/CT in Patients With Various Types of Cancer
EARLY_PHASE1 trial testing 68Ga-BNU-PSMA in Tumor in 100 participants. Status unknown.
30 December 2022
Quick facts
| Lead sponsor | First Affiliated Hospital of Fujian Medical University |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 100 |
| Start date | 21 August 2020 |
| Primary completion | 30 December 2022 |
| Estimated completion | 30 December 2022 |
| Sites | 1 location across China |
Drugs / interventions tested
- 68Ga-BNU-PSMA
Conditions studied
- Tumor — all drugs for Tumor →
- Positron-Emission Tomography — all drugs for Positron-Emission Tomography →
- Metastasis — all drugs for Metastasis →
Sponsor
First Affiliated Hospital of Fujian Medical University
Who can join
Adults 18 to 90, any sex, with Tumor or Positron-Emission Tomography. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To evaluate the potential usefulness of 68Ga-BNU-PSMA positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various types of cancer.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
<sup>68</sup>Ga-DOTA-DiPSMA PET/CT Imaging: Biodistribution, Dosimetry, and Preliminary Application in Prostate Cancer.
Zhang J, Lin Z, Zhang X, Lin R, et al · · 2021 · cited 2× · PMID 35155411 · DOI 10.3389/fbioe.2021.811972
Verify or expand the search:
- PubMed search for NCT04525612
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Tumor
Currently open trials in the same condition.
- NCT07399652 — Artificial Intelligence-Guided Detection of Blood Vessels to Enhance Safety in Third-Space Endoscopic Procedures · NA · recruiting
- NCT07382752 — Decoupling Immunotherapy Toxicity and Cancer Response · recruiting
- NCT07464132 — Application of [68Ga]Ga-NI-FAPI-04 PET/CT Imaging in Fibroblast Activation Protein Related Diseases · Phase 1, PHASE2 · recruiting
- NCT07144085 — Application of ⁶⁸Ga-FXX489 (NNS309) PET/CT Imaging in Diagnosis of Tumor Diseases. · Phase 1 · recruiting
- NCT07147465 — Performance Indicators and Impact on the Care Pathway of Sequencing on the SeqOIA and AURAGEN (Seqogen) Platforms for On · recruiting
Other First Affiliated Hospital of Fujian Medical University trials
Trials by the same sponsor.
- NCT07513844 — Optimizing Parameters of Low-Intensity Focused Ultrasound for Pallidal Modulation in Huntington's Disease · NA · not yet recruiting
- NCT07337772 — Comparing Different Doses of Corticosteroids in Local Infiltration Analgesia (LIA) for Total Knee Arthroplasty · NA · recruiting
- NCT07369401 — Deep Brain Stimulation of the Nucleus Accumbens and Anterior Limb of the Internal Capsule in the Treatment of Refractory · NA · not yet recruiting
- NCT07378358 — Evaluation of AI Large Models for Diagnosis and Treatment in Real-World Cases: Multicenter Retrospective Study · recruiting
- NCT07363382 — The Value of GRPR PET Imaging for Diagnosis and Staging in Prostate Cancer · Phase 1, PHASE2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04525612 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by First Affiliated Hospital of Fujian Medical University
- Last refreshed: 9 September 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04525612.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing